Liver biopsy (LB) is still the criterion standard procedure for obtaining liver tissue for
histopathological examination and a valuable tool in the diagnosis, prognosis, and …

The past three decades have seen liver transplantation becoming a major therapeutic
approach in the management of end-stage liver diseases. This is due to the dramatic …

The Banff Working Group on Liver Allograft Pathology reviewed and discussed literature
evidence regarding antibody-mediated liver allograft rejection at the 11th (Paris, France …

The role of de novo donor-specific HLA antibodies (DSA) in liver transplantation remains
unknown as most of the previous studies have only focused on preformed HLA antibodies …

Background and Aims Tolerance is transplantation's holy grail, as it denotes allograft health
without immunosuppression and its toxicities. Our aim was to determine, among stable long …

The impact of donor-specific HLA alloantibodies (DSA) on short-and long-term liver
transplant outcome is not clearly defined. While it is clear that not all levels of …

Background & Aims A substantial proportion of pediatric liver transplant recipients develop
subclinical chronic allograft injury. We studied whether there are distinct patterns of injury …

Recent literature confirms donor-specific HLA alloantibodies (DSA) impair 5-year survival in
some but not all liver transplant recipients. In an effort to improve DSA testing's association …

Antibody-mediated rejection after liver transplantation is an under-recognised cause of
allograft injury. While definitions of acute and chronic antibody-mediated rejection have …

Background & Aims Management of long-term immunosuppression following liver
transplantation (LT) remains empirical. Surveillance liver biopsies in combination with …